S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96

G1 Therapeutics Stock Forecast, Price & News

+0.82 (+15.86%)
(As of 07/5/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.15 million shs
Average Volume
1.45 million shs
Market Capitalization
$255.83 million
P/E Ratio
Dividend Yield
Price Target

G1 Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
545.5% Upside
$38.67 Price Target
Short Interest
23.33% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
1.05mentions of G1 Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($3.87) to ($2.87) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.26 out of 5 stars

Medical Sector

223rd out of 1,426 stocks

Pharmaceutical Preparations Industry

104th out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive GTHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

G1 Therapeutics logo

About G1 Therapeutics (NASDAQ:GTHX) Stock

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

GTHX Stock News Headlines

Six questions with Incyclix Bio CEO Patrick Roberts
G1 Therapeutics Q4 2021 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$31.48 million
Book Value
$3.38 per share


Free Float
Market Cap
$255.83 million

G1 Therapeutics Frequently Asked Questions

Should I buy or sell G1 Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last twelve months. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" G1 Therapeutics stock.
View analyst ratings for G1 Therapeutics
or view top-rated stocks.

What is G1 Therapeutics' stock price forecast for 2022?

6 equities research analysts have issued 12-month price objectives for G1 Therapeutics' stock. Their GTHX stock forecasts range from $19.00 to $67.00. On average, they expect G1 Therapeutics' stock price to reach $38.67 in the next year. This suggests a possible upside of 545.5% from the stock's current price.
View analysts' price targets for G1 Therapeutics
or view top-rated stocks among Wall Street analysts.

How has G1 Therapeutics' stock performed in 2022?

G1 Therapeutics' stock was trading at $10.21 at the beginning of 2022. Since then, GTHX stock has decreased by 41.3% and is now trading at $5.99.
View the best growth stocks for 2022 here

When is G1 Therapeutics' next earnings date?

G1 Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for G1 Therapeutics

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics, Inc. (NASDAQ:GTHX) announced its quarterly earnings data on Wednesday, May, 4th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by $0.16. The business had revenue of $6.90 million for the quarter, compared to analyst estimates of $5.78 million. G1 Therapeutics had a negative trailing twelve-month return on equity of 107.75% and a negative net margin of 708.20%. During the same quarter in the previous year, the firm earned ($0.65) EPS.
View G1 Therapeutics' earnings history

Who are G1 Therapeutics' key executives?

G1 Therapeutics' management team includes the following people:
  • Mr. John E. Bailey Jr., CEO, Pres & Director (Age 57, Pay $1.04M)
  • Ms. Jennifer K. Moses CPA, Chief Financial Officer (Age 47, Pay $606.27k)
  • Dr. Mark A. Velleca M.D., Ph.D., Sr. Advisor & Director (Age 58, Pay $242.69k) (LinkedIn Profile)
  • Dr. Rajesh K. Malik Ch.B., M.B., M.D., Chief Medical Officer and Sr. VP of R&D (Age 63, Pay $596.37k)
  • Mr. Mark Avagliano, Chief Bus. Officer (Age 46, Pay $606.05k)
  • Mr. Andrew Perry, Chief Commercial Officer (Age 49, Pay $568.6k)
  • Mr. Terry L. Murdock, Chief Operating Officer (Age 62)
  • Mr. Alexander D. Smith M.S., VP of Technical Operations
  • Dr. Jay C. Strum Ph.D., Chief Scientific Officer (Age 58)
  • Mr. William C. Roberts, VP of Investor Relations & Corp. Communications (Age 53)

What other stocks do shareholders of G1 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE).

When did G1 Therapeutics IPO?

(GTHX) raised $101 million in an initial public offering (IPO) on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

What is G1 Therapeutics' stock symbol?

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

How do I buy shares of G1 Therapeutics?

Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is G1 Therapeutics' stock price today?

One share of GTHX stock can currently be purchased for approximately $5.99.

How much money does G1 Therapeutics make?

G1 Therapeutics (NASDAQ:GTHX) has a market capitalization of $255.81 million and generates $31.48 million in revenue each year. The company earns $-148,350,000.00 in net income (profit) each year or ($4.03) on an earnings per share basis.

How many employees does G1 Therapeutics have?

G1 Therapeutics employs 148 workers across the globe.

How can I contact G1 Therapeutics?

G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The official website for G1 Therapeutics is www.g1therapeutics.com. The company can be reached via phone at (919) 213-9835, via email at jmacdonald@g1therapeutics.com, or via fax at 919-741-5830.

This page (NASDAQ:GTHX) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.